Dr. Allan on the Use of Vecabrutinib Therapy in B-Cell Malignancies

Video

John N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.

John N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.

Vecabrutinib is 1 of 3 investigational BTK inhibitors that is being evaluated in patients with B-cell malignancies. Vecabrutinib is unique from the currently approved BTK inhibitors in that it is reversible and noncovalent, explains Allan. When patients progress on irreversible, covalent BTK inhibitors, they typically acquire a resistance mutation; this is not the case with the reversible BTK inhibitors, says Allan.

The drug is currently under evaluation in a phase Ib/II trial. To be eligible for enrollment, patients had to have received ≥2 prior lines of therapy and progressed on a covalent BTK inhibitor, adds Allan. Several histologic subtypes have accrued to the trial, including those with chronic lymphocytic leukemia, Waldenström Macroglobulinemia, marginal zone lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. To date, 29 patients have enrolled on the trial, results regarding these patients were presented at the 2019 ASH Annual Meeting, concludes Allan.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.